Abstract
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6) which might be important in the pathogenesis of interstitial pneumonia.
Objective to evaluate efficacy of tocilizumab in COVID-19 pneumonia patients.
Design multicenter single-arm phase 2 trial, powered to detect 10% absolute lethality rate reduction at 14 and 30-days, with 20% and 35% expected rates. A consecutive prospective validation cohort was also evaluated.
Setting 185 Italian public hospitals, during coronavirus breakout.
Patients 1221 patients hospitalized with pneumonia, from March 19th to 24th, 2020.
Intervention tocilizumab 8 mg/kg, intravenously, one or two administrations with 12 hours interval.
Measurements lethality rates at 14 and 30-days; safety according to CTCAE.
Results 301 and 920 cases were available for intention-to-treat (ITT) analysis in phase 2 and validation cohorts. Due to delayed drug availability, 60% of patients received tocilizumab, and with some delays. In phase 2, 67 patients died; lethality rates were 18.4% (97.5%CI: 13.6-24.0, P=0.52) and 22.4% (97.5%CI: 17.2-28.3, P<0.001) at 14 and 30-days. Lower rates (15.6% and 20.0%) were reported in the modified ITT including only treated patients (mITT). Lethality rates in the validation cohort were smaller than in phase 2, at 14 and 30 days and in ITT and mITT populations. Multivariable logistic regression model suggests tocilizumab be more effective in patients not requiring mechanical respiratory support at baseline. No relevant signal of specific drug toxicity was reported, many severe adverse events being disease-related.
Limitations single-arm design. In addition, delayed availability of the drug induced indication bias and immortal time bias.
Conclusion Tocilizumab reduced lethality rate at 30 but not at 14-days, compared with the expectations, without significant toxicity. Efficacy was more evident among patients not requiring mechanical respiratory support.
Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)
Funding No specific funding was available for the study. Tocilizumab was provided by Roche free of charge.
Competing Interest Statement
Dr. Perrone reports grants, personal fees and non-financial support from Bayer; grants and personal fees from Incyte, Astra Zeneca, Pierre Fabre; personal fees from Celgene, Janssen Cilag, Roche, Pfizer, Sandoz, outside the submitted work. Dr. Piccirillo reports grants and personal fees from AstraZeneca; grants from Roche; personal fees from Daichii Sankyo, GSK, MSD; non-financial support from Bayer, outside the submitted work. Dr. Ascierto reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees and other from MSD; personal fees from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, outside the submitted work. Dr. Salvarani reports grants and personal fees from Roche; personal fees from Sanofi-Genzyme, Abbvie, Pfizer, Eli-Lilly, Novartis, outside the submitted work. Dr. Castelli reports grants from Gilead, ViiV, GSK, Janssen, Eiger, Roche, Gilead, outside the submitted work. Dr. Gravina reports non-financial support from Pfizer, outside the submitted work. Dr. Lichtner reports grants from Gilead; personal fees from Abbvie, Merck, Janseen, Angelini, outside the submitted work.
Clinical Trial
NCT04317092
Clinical Protocols
http://www.repo.epiprev.it/1604
http://www.repo.epiprev.it/1610
Funding Statement
No specific funding was available for this study. Tocilizumab was provided by the pharmaceutical company (Roche) free of charge. The National Cancer Institute of Naples was the sponsor of the study and had full property of data and full access to them and final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
According to a specific Italian law, TOCIVID-19 was approved for all Italian centers by the National Ethical Committee at the Lazzaro Spallanzani Institute on March 18th, 2020; two amendments followed on March 24th, 2020 and April 28th, 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available in the near future.
